Hormonal
Hypertension and hyperlipidemia prevalence increases significantly with age, reaching 56% and 45% respectively in the elderly (≥65 years), indicating that age is a critical modifier for cardiovascular risk.
The risk of high blood pressure and high cholesterol rises sharply as you age, affecting more than half of the elderly population. However, these risks start rising in middle age. Regular monitoring and maintaining a healthy diet and activity level can help manage these risks at any age, not just in old age.
The same pattern was found for hypertension with the prevalence mounting to 56% (51.2% in males, 61% in females; p < 0.05) in the elderly compared to 1.7% in adults aged 20–39 and 17.3% in the 40–65 age group... prevalence of dyslipidemia and hypertension reaching 45 and 57% in the elderly, respectively.
Why this rating
Large, representative sample with clinical measurements for blood pressure and lipid profiles.
Source
Aims, design and preliminary findings of the Hellenic National Nutrition and Health Survey (HNNHS)
HNNHS Contributors et al. · BMC Medical Research Methodology · 2019
DOI 10.1186/s12874-018-0655-y
More from this paper
- In the Greek adult population, the combined prevalence of overweight and obesity is approximately 47.5%, with significant gender and age-related variations where males exhibit higher overweight prevalence and obesity rates increase with age.Good
- High prevalence of modifiable risk factors, specifically smoking (50.4% active smokers) and alcohol consumption (72.4% regular consumers), are strongly associated with the high rates of chronic diseases like hypertension and hyperlipidemia in the Greek population.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →